In an eight -
year trial involving almost 50,000 women, roughly half the participants went on a low - fat diet, while the others did not.
An eight -
year trial involving almost 50,000 women suggested that that's highly unlikely.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full
year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical
trials involving investigational compounds; Gilead's ability to initiate clinical
trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
A new book on the Canadian workplace — Work on
Trial: Canadian Labour Law Struggles, edited by Judy Fudge and Eric Tucker — provides an engaging and accessible account of various labour battles in the courts over the past 85
years involving human rights, employment fairness and union recognition.
The readers, which were tested during a
trial involving 40 churches last
year, are capable of supporting 500 transactions without recharging, although the vast bulk of regular donating is expected to continue by standing order.
Involved with these considerations is the question of the
year in which the last supper and the
trial and crucifixion of Jesus took place.
Although the parmesan cheese cases were recently dismissed, the defendant companies were
involved in contentious litigation for more than a
year before the
trial - level court dismissed the action.
For the very lucky, you only have to clean up a small pond's worth of pee over the course of a few weeks before you're in the clear, but for most people, potty training a kid
involves a series of
trials and tribulations that can take months (or in some cases
years; our thoughts are with you).
Talk about ethics reform in the new legislative session has been largely muted this
year, even as a
year filled with corruption
trials involving prominent New York figures is underway, including the ongoing
trial this week of Joe Percoco, a former close aide to Governor Andrew Cuomo.
Next
year, a former top aide to Gov. Andrew Cuomo, Joe Percoco, will go on
trial along with the former president of SUNY Nanotech and upstate developers, who are accused of being
involved in a bribery and bid - rigging scheme for economic development projects.
The Silver retrial is the second of four corruption
trials involving state government to take place this
year.
Several former close associates go on
trial later this
year on bribery and bid - rigging charges in connection with a corruption scandal
involving the governor's signature economic development projects.
«Your brother did not die in vain,» stated Cuomo of Brodwer's brother Kalief, who committed suicide in 2015, two
years after being released from Rikers Island, where he had spent three
years awaiting
trial on charges
involving a stolen backpack.
DeFrancisco, 71, immediately emphasized what he sees as the governor's vulnerabilities: several economic development projects in upstate New York that have sputtered, chronic delays in the New York City subway system and a corruption
trial involving the 60 -
year - old governor's close confidant Joe Percoco — the first of six
trials this
year involving state figures.
After 6 weeks of studying the over one
year court proceedings on the ongoing
trial involving four suspects; Osarfo Anthony, Ekow Micah, Sarah Kwablah, and Chris Handler, accused of allegedly conspiring to extort money from Asamoah Gyan, the new Attorney General headed by Madam Gloria Akuffo, is set to appear in court for
trial to continue.
Next
year will also feature two federal corruption
trials involving some of Cuomo's top allies: Alain Kaloyeros, the former president of State University of New York Polytechnic Institute, and Joe Percoco, who managed Cuomo's past two campaigns and has been likened to a brother.
Another corruption
trial scheduled to begin this
year involves Alain Kaloyeros, who was president of SUNY Polytechnic Institute and is accused of rigging bids for projects part of the «Buffalo Billion,» one of Cuomo's top economic development programs.
New York Gov. Andrew Cuomo has spent the past few weeks laying out his agenda for the
year, but a federal bribery
trial starting Monday
involving a former aide could distract from his plans.
The
year after his
trial, the U.S. Supreme Court, in a case
involving Bob McDonnell, ex-governor of Virginia, narrowed the types of official actions that would constitute quid pro quo.
Nine people have pleaded guilty or been indicted in connection with alleged bid rigging and other corruption charges
involving some of Governor Cuomo's economic development programs, and they face
trial later this
year.
Several former close associates go on
trial later this
year on bribery and bid rigging charges, in connection with a corruption scandal
involving the governor's signature economic development projects.
«I've been
involved in clinical
trials for 30
years,» says the study's lead author Bonnie Ramsey, a professor of pediatrics at the University of Washington School of Medicine in Seattle.
After pooling the results of 27
trials involving 165,149 people, the meta - analysis reported that people are 21 percent less likely to suffer a serious vascular event such as a heart attack, stroke or bypass surgery after their cholesterol drops by the amount that might be expected after taking statins for a
year than are similar people who do not take the pills.
«There are currently no therapies which successfully reverse the damage seen in the more than 12,000 individuals who suffer a spinal cord injury each
year in the United States alone,» says Dr. Richard G. Fessler, professor of neurological surgery at Rush University Medical Center and principal investigator for the Phase 1 clinical
trial involving AST - OPC1 (oligodendrocyte progenitor cells).
The
trial, which began in 2001 and spanned 13
years,
involved 24 people with a severe form of MS.. During that period, the positive results endured.
Her team reviewed data from 20 clinical
trials in Europe, Australia, New Zealand and Taiwan that
involved more than 4,800 children whose mothers either took probiotics during pregnancy or gave probiotics to their babies in the first
year.
It typically takes many
years to initiate such
trials because of the stringent safety testing that must be done before testing in humans begins, but Reynolds said it may be possible to move faster as the therapy only
involves modifying a patient's dietary intake and supplementing with a medium - chain triglyceride oil, both of which have no known side effects.
The
trials lasted from 3 months to 6
years, and the children
involved were followed up for various lengths of time after the
trials had ended.
Kovatchev has racked up nearly 184,000 patient - hours, and counting, of clinical
trials involving his version of an artificial pancreas — the time equivalent of one person wearing his device for more than 20
years.
However, Esther and the UNC coauthors, who were not
involved in the clinical
trial, said that a statistically significant increase in lung function is thought to lead to fewer CF - related flare - ups over the course of a
year.
The new six -
year study, «Cognitive enhancement therapy for adult autism spectrum disorder: Results of an 18 - month randomized clinical
trial,»
involved 54 adults and was led by Shaun Eack, Ph.D., M.S.W., Pitt's David E. Epperson Professor of Social Work and Psychiatry, and Nancy Minshew, M.D., Pitt professor of psychiatry and neurology.
Beer's team of prostate cancer researchers at OHSU's Knight Cancer Institute have been
involved in, or led, clinical
trials for three of the five new treatments developed for prostate cancer in recent
years.
Analysis of data from nine randomised
trials involving 6756 patients (1729 older than 80
years of age) showed that alteplase treatment significantly increased the odds of a good stroke outcome (no significant disability 3 - 6 months after stroke), with faster treatment offering the best chance of recovery.
New results from a clinical
trial involving more than 900 military veterans at high risk for keratinocyte carcinoma skin cancer provides evidence that using the generic skin cream fluorouacil 5 percent for two to four weeks may reduce the risk of a squamous cell carcinoma (SCC) needing surgery by 75 percent within a
year.
«The intervention was effective, even though most
trial participants reported pain that had been present for many
years, that
involved multiple sites, and that had been unsuccessfully treated with numerous analgesics,» the authors write.
This latest
trial involved 320 children aged 4 to 11
years from 43 family practices in the UK who had recent histories of otitis media and effusion with confirmed fluid in one or both ears.
They reviewed data from 80
trials involving 205,401 children aged six months to twelve
years, mostly in low and middle income countries.
The
trial involved 12 patients (6 women, 6 men) with moderate to severe depression (average length of illness was 17.8
years).
An earlier form of the vaccine was used in the DarDar
Trial, a seven -
year study in Tanzania sponsored by the U.S. National Institutes of Health
involving patients with HIV infection who at birth had received BCG, the current tuberculosis vaccine.
The multicenter
trial involving 100 patients showed that the addition of ipilimumab to nivolumab, which is currently FDA - approved for treatment of kidney cancer, leads to responses that can last beyond two
years.
«They are the most rigorous double - blind placebo - controlled
trials of a psychedelic drug in the past 50
years,» writes David Nutt, a pharmacologist at Imperial College London who was not
involved in the work, in an editorial accompanying the papers.
In one
trial involving 53 children with acute lymphoblastic leukaemia — the disease that Layla had — for whom conventional therapies had not worked, 29 are still in remission months or
years after treatment.
In a Canadian
trial involving 16 asthma patients, the procedure improved average air - flow rates in and out of the lungs, even when tested two
years after treatment.
@Ham: The startup is venture funded, which means the people
involved most likely think they are only a
year or two away from therapies that will work in people, ready for
trials to begin.
Later - phase clinical
trials, which often take several
years or more to conduct, often
involve hundreds or thousands of patients.
Despite the studious modesty of that hope, a handful of clinical
trials involving Tregs in transplantation and autoimmune diseases are already underway, and the coming
years are poised to see a crop of promising clinical leads for cancer treatment.
Krebs will work on a similar, larger
trial later this
year involving patients who take high - dose opioids.
The
trial, a first in islet transplantation, is slated to begin in the fall of this
year and will
involve approximately 32 new transplants at up to eight clinical centers across North America and Europe.
To verify the effectiveness of aducanumab, a
trial was set in place that
involved 165 people receiving the drug and over the course of one
year it was reported that the amyloid - beta levels in these people's brains had declined.
The challenge takes on even more urgency with recent developments, including a federal administration now more open to exploring the potential of stem cells, the recent FDA approval of a human
trial involving embryonic stem cells, as well as the reported case of a young boy who developed a brain tumor four
years after receiving a stem - cell treatment for a rare genetic disorder.